Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 partial crossover study of subcutaneous C1 esterase inhibitor for hereditary angioedema prophylaxis
2015-002478-19Phase 3Completed
- Sponsor
- ViroPharma Incorporated
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (3 arms), sponsored by ViroPharma Incorporated. Primary endpoint: Normalized number of attacks. Started Dec 2015; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2015-002478-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002478-19.